We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
SPDR S&P Telecom ETF | AMEX:XTL | AMEX | Exchange Traded Fund |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
1.21 | 1.71% | 71.555 | 71.62 | 70.27 | 70.36 | 11,974 | 20:33:19 |
RNS Number:2908T XTL Biopharmaceuticals Limited 16 December 2003 XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today announces an update on recent clinical progress and corporate developments to investors and analysts. Highlights: - Phase 2 trial initiated with HepeX(TM)-B in hepatitis B patients for the prevention of infection following liver transplant - Interim clinical results for HepeX(TM)-C dose escalation trial - Progress in discussions on HepeX(TM) corporate alliances HepeX(TM)-B Update: dosing commenced in Phase 2b trial XTLbio has commenced dosing in a Phase 2b trial with HepeX-B for the prevention of re-infection in hepatitis B patients following liver transplant. The trial is being conducted in the US, Europe and Israel and involves 45 patients. Patients receiving the current first-line preventative treatment, blood derived polyclonal hepatitis B immune globulin (HBIg) solution together with lamivudine, will be randomised to three cohorts; one cohort continuing on the standard preventative treatment and two cohorts receiving different doses of HepeX-B together with lamivudine. The goal of the study is to demonstrate that replacement of HBIg with HepeX-B in the current prophylaxis protocol in HBV liver transplant patients is effective in preventing HBV re-infection. Patients will be treated over a six-month period, with a 12-month follow-on observation period. Primary endpoints will be HBV DNA and HBV antigen levels. Secondary endpoints will be anti-HBV antibody blood levels and the safety of HepeX-B compared to the current drug. HepeX-B is a combination of two fully human monoclonal antibodies acting on the hepatitis B virus surface antigen, which were selected based on their strong activity against the virus in XTLbio's pre-clinical Trimera(TM) model. In a recently reported study, HepeX-B maintained serum levels similar to or higher than the current first-line treatment (HBIg), while using 1,000 times less drug. In August this year, HepeX-B was granted Orphan Drug Designation from the US Food and Drug Administration, giving the product exclusive marketing rights in the US for seven years following marketing approval. Dr Neil Graham, Chief Medical Officer of XTLbio, said: "Chronic hepatitis B is the most common serious liver infection in the world and can be fatal for patients whose disease progression necessitates a liver transplant. In the phase 2 trial announced today, we hope to be able to confirm the beneficial effects of HepeX-B seen in earlier studies and show a meaningful benefit to patients who have undergone liver transplant." HepeX(TM)-C Update: Interim clinical results from dose escalation trial XTLbio discloses preliminary clinical results from its Phase 2a randomised placebo controlled dose-escalation / safety study on HepeX-C. The interim results involved 12 HCV associated liver transplant patients who received the low dose regimens of HepeX-C for three months after their transplants. Based on the absence of drug related severe adverse events on these initial twelve patients together with amendments to include additional cohorts, the FDA has permitted the higher dosing regimen. XTLbio is now proceeding with completing the higher dose cohorts in the 24 patient study. HepeX-C is a fully human high-affinity monoclonal antibody, which was shown to reduce viral levels of the HCV virus in chronic HCV patients in a Phase 1b dose ranging safety study. Based upon safety data generated in that study, XTLbio decided to clinically evaluate HepeX-C in liver transplant patients infected with HCV. The study is aimed at achieving the minimum dose necessary of HepeX-C to bind all free HCV virus in the blood stream and thereby prevent or delay re-infection of the transplanted liver with HCV, known as "antibody excess". It is believed antibody excess could potentially prevent or significantly delay re-infection of patients with HCV after their transplant. The continuation of the dose escalation study in 12 additional patients is designed to find the minimum dose necessary to achieve antibody excess while demonstrating safety. Dr. Shlomo Dagan, XTLbio's Chief Scientific Officer, stated: "As reported at the recent AASLD liver meeting in Boston, one of the most critical needs for liver transplant specialists today is to find an approach to limit the devastating effects of HCV re-infection. The prognosis for such patients begs for a solution. Our strategy to achieve antibody excess is fully justified based upon our review of the data. Therefore we look forward to completing this trial in HepeX-C in transplant recipients." Business Development Update XTLbio is making progress to secure an alliance on our HepeX programs. Securing a partner for one or more of our products remains the key priority for XTLbio. Glenn Kazo, Chief Business Officer of XTLbio, said: "We are encouraged by the high level of interest shown in our pipeline and are in discussions of various stages with a number of potential partners. It is our intention to conclude a value enhancing partnership at the earliest possible opportunity and we are working continuously to achieve this." Contacts: XTLbio Dr. Martin Becker, President and CEO, Tel: +972-8-930-4440 Glenn Kazo, CBO, Tel: +1-603-878-9857 Financial Dynamics David Yates, Sarah MacLeod, Tel: +44 (0) 20 7831 3113 Notes to Editors XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing drugs against hepatitis. XTLbio's HepeX(TM) product line - now in clinical trials - has the potential to introduce revolutionary therapies for viral hepatitis, including prevention of re-infection in transplanted livers, the Company's primary focus, and a longer-term cocktail approach in treating chronic illness. XTLbio believes its primary competitive advantage lies in its patented Trimera(TM) technology, which enables the development of fully human monoclonal antibodies and models of human disease for pre-clinical drug validation. Established in 1993, XTLbio became a public company in 2000 with shares traded on the London Stock Exchange under the symbol XTL. About HBV-related liver transplant prophylaxis Hepatitis B is the most common form of hepatitis and one of the world's leading causes of death. About 5% of chronic hepatitis B patients will develop end-stage liver disease, a condition, which necessitates liver transplantation. During the liver transplantation procedure the diseased liver is removed and a healthy liver from a donor is transplanted. Without proper treatment, the newly transplanted liver can become re-infected by residual virus in the patient's serum, leading to rapid disease progression and graft failure in many cases. The current market for prevention of hepatitis B infection following liver transplant is estimated to be worth $100 million. About hepatitis C Hepatitis C is a major public health concern. The World Health Organization estimates that 170 million people worldwide are chronic carriers of the hepatitis C virus (HCV) and that 3 to 4 million people are newly infected each year. It is expected that 25 to 35% of these chronic patients will develop progressive liver disease including cirrhosis and liver cancer. Hepatitis C is the single leading cause of liver transplantation. The US Centres for Disease Control and Prevention estimate that approximately 4 million people in the United States (almost 2% of the population) have been infected with HCV, of whom, approximately 3 million are chronically ill. Hepatitis C is the cause of an estimated 8,000 to 10,000 deaths annually in the US. About HCV-related liver transplant prophylaxis Approximately 5% of chronic HCV patients will develop end-stage liver disease, and ultimately may require liver transplantation. Today, there is a major problem associated with HCV-related liver transplantation. Although the infected liver - the major source of viral replication - has been removed, free-floating virus in the patient's serum re-infects the healthy transplanted liver in a matter of weeks. Disease progression in re-infected patients is several times faster and, in many cases, a re-transplant becomes necessary. At present, there is no available solution to this problem. The Company estimates worldwide annual sales potential for HCV liver transplant prophylaxis at US$400 million. About the treatment of chronic hepatitis C The existing first-line chronic HCV therapy is often associated with a 50-60% chance of success but is limited by severe side effects, including anaemia, fatigue, hair loss and depression. Due to the relatively limited efficacy and toxicity of this treatment, chronic HCV is still considered an unmet medical need. Financial analysts estimate that worldwide annual sales for all products treating chronic hepatitis C could reach US$4 billion in 2004. HepeX(TM), Trimera(TM), XTL(TM) and XTLbio(TM) are trademarks of XTL Biopharmaceuticals Ltd. This information is provided by RNS The company news service from the London Stock Exchange END MSCUVVWROARUAAA
1 Year SPDR S&P Telecom ETF Chart |
1 Month SPDR S&P Telecom ETF Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions